Clinical effect of ginkgo leaf tablets on clinical outcomesof patients with forgotten-type mild cognitive impairment and its effect on soluble receptor for advanced glycation end products and soluble low-density lipoprotein receptor-associated protein 1
10.7619/jcmp.201724008
- VernacularTitle:银杏叶片对遗忘型轻度认知功能障碍患者的临床疗效及对可溶性糖基化终末产物受体、可溶性低密度脂蛋白受体相关蛋白1的影响
- Author:
Weixia GU
1
;
Jun XU
;
Zhiqing ZHUANG
;
Xingrong YE
;
Molan WANG
;
Jun ZHU
Author Information
1. 扬州大学附属五台山医院神经内科
- Keywords:
ginkgo leaf tablets;
forgotten-type mild cognitive dysfunction;
efficacy;
soluble glycosylated terminal product receptor;
soluble low-density lipoprotein receptor-associated protein 1
- From:
Journal of Clinical Medicine in Practice
2017;21(24):27-29,33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of ginkgo leaf tablets in patients with forgotten-type mild cognitive impairment (aMCI) and its effect on soluble glycosylated terminal product receptor (sRAGE) and soluble low-density lipoprotein receptor-associated protein 1 (sLRP-1).Methods A total of 124 patients with aMCI were divided into observation group (n =62) and control group (n =62),treated by nimodipine tablets (30 mg) three times a day,ginkgo leaf tablets for 3 times a day,respectively.The changes of MoCA score,levels of sRAGE,sLRP-1 and the occurrence of adverse reactions before and after treatment were compared between the two groups.Results The scores of MoCA were improved in both groups after treatment,and the observation group improved more after treatment,and the differences were statistically significant (P ＜ 0.0 5).There was no significant difference in plasma sRAGE and sLRP-1 levels between the two groups (P ＞ 0.05),but the plasma sRAGE increased and the sLRP-1 level decreased after treatment in two groups (P ＜ 0.05).Plasma sRAGE was higher in the treatment group than that in the control group,while the sLRP-1 level was lower than that in the control group (P ＜0.05).Conclusion Ginkgo leaf tablets have a significant clinical effect for aMCI patients,which can increase level of plasma sRAGE and decrease sLRP-1.
